Tibet Pharmaceutical announced that revenue for the semi-year 2026 was 1,554 billion yuan, down 5.83% year on year; net profit attributable to shareholders of listed companies was 608 million yuan, up 7.16% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 440 million yuan, down 19.00% year on year. The company plans to distribute a cash dividend of 1.15 yuan per share to all shareholders based on the total share capital after deducting the repurchase of special account shares.

Tibet Pharmaceutical announced that revenue for the semi-year 2026 was 1,554 billion yuan, down 5.83% year on year; net profit attributable to shareholders of listed companies was 608 million yuan, up 7.16% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 440 million yuan, down 19.00% year on year. The company plans to distribute a cash dividend of 1.15 yuan per share to all shareholders based on the total share capital after deducting the repurchase of special account shares.